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Abstract
Background: Treatment of tumors with macromolecular toxins directed to cytoplasmic targets requires selective
endocytosis followed by release of intact toxin from the endosomal/lysosomal compartment. The latter step
remains a particular challenge. Claudins 3 and 4 are tight junction proteins that are over-expressed in many types
of tumors. This study utilized the C-terminal 30 amino acid fragment of C. perfringens enterotoxin (CPE), which
binds to claudins 3 and 4, to deliver a toxin in the form of recombinant gelonin (rGel) to the cytoplasm of the
human ovarian carcinoma cell line 2008.
Results: CPE was fused to rGel at its N-terminal end via a flexible G4S linker. This CPE-G4S-rGel molecule was
internalized into vesicles from which location it produced little cytotoxicity. To enhance release from the
endosomal/lysosomal compartment a poly-arginine sequence (R9) was introduced between the CPE and the rGel.
CPE-R9-rGel was 10-fold more cytotoxic but selectivity for claudin-expressing cells was lost. The addition of a poly-
glutamic acid sequence (E9) through a G4S linker to R9-rGel (E9-G4S-R9-rGel) largely neutralized the non-selective
cell membrane penetrating activity of the R9 motif. However, introduction of CPE to the E9-G4S-R9-rGel fusion
protein (CPE-E9-G4S-R9-rGel) further reduced its cytotoxic effect. Treatment with the endosomolytic reagent
chloroquine increased the cytotoxicity of CPE-E9-G4S-R9-rGel. Several types of linkers susceptible to cleavage by
furin and endosomal cathepsin B were tested for their ability to enhance R9-rGel release but none of these
modifications further enhanced the cytotoxicity of CPE-E9-G4S-R9-rGel.
Conclusion: We conclude that while a claudin-3 and -4 ligand serves to deliver rGel into 2008 cells the delivered
molecules were entrapped in intracellular vesicles. Incorporation of R9 non-specifically increased rGel cytotoxicity
and this effect could be masked by inclusion of an E9 sequence. However, the putative protease cleavable
sequences tested were inadequate for release of R9-rGel from CPE-E9-G4S-R9-rGel.
Background
The claudin (CLDN) family of transmembrane proteins
plays an integral role in the formation and function of
tight junctions. Using gene expression profiling, we and
others have found that claudin-3 (CLDN3) and claudin-
4 (CLDN4) genes are highly expressed in ovarian
cancers [1-3]. In addition, several other studies have
reported aberrant claudin expression in various cancers.
Some examples include increased expression of
CLDN3 and CLDN4 in prostate and uterine cancers
[4,5], and high CLDN4 expression in pancreatic cancer
[6,7]. These two genes are not normally highly expressed
in non-malignant human tissues including the normal
ovarian epithelium [8], clearly associating abundance of
these two proteins with malignancy. Although their
functional role in cancer development and progression
remains unclear, the differential expression of these pro-
teins between tumor and normal cells makes them
prime candidates for cancer targeted therapy [9].
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Preclinical studies have shown that tumor cells over-
expressing CLDNs can be successfully targeted both in
vitro and in vivo by a fusion protein composed of the
C-terminal fragment (amino acids 184 to 319) of Clos-
tridium perfringens enterotoxin (CPE), a natural ligand
for CLDNs, and the protein synthesis inhibitory factor
(PSIF) which lacks the cell binding domain of Pseudo-
monas exotoxin [10,11]. When CPE binds to CLDNs it
triggers endocytosis most likely via a clathrin-dependent
process. We previously reported in vitro characterization
of a fusion protein, CPE290-319-TNF, and demonstrated
that the C-terminal 30 amino acids (amino acids
290-319) of CPE could effectively target TNF to ovarian
cancer cells expressing claudin-3 and claudin-4 [12].
Gelonin (rGel) is a class I ribosome-inactivating protein
derived from the plant Gelonium multiforum. Similar in
action to other plant toxins such as ricin, gelonin induces
cell death by removing the base A4324 in 28 s rRNA
which prevents the association of elongation factor-1 and
-2 (EF-1 and EF-2) with the 60 s ribosomal subunit, even-
tually causing cell death in eukaryotic cells [13]. Since
gelonin functions enzymatically, only a few molecules are
needed to kill a cell, but by itself gelonin has very limited
toxicity because it is not able to cross the plasma mem-
brane at levels that are therapeutically useful. This has
prompted the development of strategies to improve intra-
cellular accumulation. Gelonin has been used to construct
a large number of different kinds of immunotoxins, some
of which are currently undergoing clinical testing [14-16].
Cancer therapies that exploit targeting ligands to deli-
ver attached cytotoxic drugs selectively to malignant cells
are currently receiving significant attention. However, the
lipophilic nature of the biological membranes restricts
the direct intracellular delivery of such compounds.
While some short peptides can enter cells, the cell mem-
brane prevents large molecules, such as proteins and
DNA, from entering cells unless there is an active trans-
port mechanism. Under certain circumstances these
molecules, or even small particles, can be transferred
from the extracellular space into cells by the receptor-
mediated endocytosis. However, the problem is that most
molecules or particles entering the cell via the endocytic
pathway become entrapped in endosomes and eventually
get degraded in the lysosomal compartment. As a result,
only a small fraction of active material reaches the cyto-
plasm. It has been reported that a poly-arginine tract
such as R9, which is also a furin cleavage site, can aid in
translocating a recombinant pro-apoptotic protein target-
ing the HER2 receptor from the endosomal to the cytoso-
lic compartment leading to enhanced cell killing activity
[17]. However, due to the fact that all the arginine-rich
cell-penetrating peptides (CPPs) induce a strong non-
specific cell binding, they lack cell specificity and this
remains the major impediment to development. Tsien
and coworkers [18] previously developed a new strategy,
designated “activatable cell penetrating peptides (ACPP)”
by which the cellular association of the positively charged
R9 is effectively blocked by fusing it to a domain made up
of negatively charged glutamates (E9) via a cleavable lin-
ker. Adsorption and cellular uptake of the CPP portion
and its attached cargo are inhibited until the linker is
cleaved by a tumor protease. In the present study, we
describe the construction and characterization of several
rGel-based chimeric toxins composed of different combi-
nations of CPE290-319, R9 and E9. We have used these to
examine how these modules affect the internalization
and cytotoxic activity when tested against CLDN-expres-
sing ovarian cancerous cells.
Methods
Reagents
Tissue culture media were purchased from Life Tech-
nologies (Frederick, MD), pE-SUMOstar vector and
SUMOstar protease 1 from LifeSensors, Inc (Malvern,
PA), and metal-affinity resin Ni-NTA agarose from Qia-
gen (Valencia, CA). Rabbit anti-gelonin antibody was a
gift from Dr. Michael G. Rosenblum (MD Anderson
Cancer Center, Houston, TX). Texas red-labeled sec-
ondary antibodies against rabbit immunoglobulin were
obtained from Jackson ImmunoResearch Laboratories,
Inc (West Grove, PA).
Cells and cell culture
The human ovarian carcinoma cell line 2008 that expresses
both CLDN3 and CLDN4 and its CLDN3 knockdown sub-
line 2008-CLDN3KD-4.5 [12] were grown in RPMI
1640 supplemented with 5% fetal bovine serum. Cultures
were maintained at 37°C in a humidified atmosphere of 5%
CO2 and 95% air.
Plasmid construction
The gene encoding gelonin in the pET-32 bacterial
expression vector was kindly supplied by Michael
G. Rosenblum [19]. Recombinant fusion toxins contain-
ing rGel and either CPE390-319 or E9/R9 with the flexible
linker (GGGGS, designated “G4S”) were constructed by
splicing overlap extension PCR. All the fusion genes
were cloned into the T7 promoter-based E. coli expres-
sion vector pE-SUMOstar. All the constructed plasmids
were sequence-verified and transformed into E. coli
strain BL21(DE3) pLysS.
Protein expression in E. coli
To express the recombinant fusion proteins, bacterial cul-
tures were incubated at 37°C in LB growth medium with
200 μg/mL ampicillin and grown to log phase (A600 = 0.8).
The target protein expression was induced at 18°C with
0.1 mmol/L isopropyl-Lthio-b-D-galactopyranoside for
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6 h. Induced bacterial cultures were then centrifuged and
stored frozen at -20°C overnight.
Isolation and purification of fusion toxins
Frozen bacterial pellets were allowed to thaw with the addi-
tion of 50 mmol/L Na-phosphate (pH 7.6), 300 mmol/L
NaCl, 10 mmol/L imidazole and 100 μg/ml lysozyme. The
bacterial suspension was sonicated and then clarified by
centrifugation at 14,000 g for 30 min at 4°C to pellet the
cellular debris. The supernatant that contained the soluble
fraction of the recombinant protein was loaded onto a
Ni-NTA column pre-equilibrated with the same lysis buffer.
After washing the column twice with a wash buffer (50 mM
NaH2PO4, 300 mM NaCl and 20 mM imidazole, pH 8.0),
the bound proteins were eluted with a elution buffer
containing 50 mM NaH2PO4, 300 mM NaCl and 250 mM
imidazole (pH 8.0). Absorbance (280 nm) and sodium
dodecylsulfate polyacrylamide gel electrophoresis (SDS-
PAGE) analyses were performed to determine which frac-
tion(s) contained the majority of polyhistidine-tagged (6 ×
His tag) protein. Fractions were combined and dialyzed
against 20 mM Tris-HCl (pH 8.0) and 150 mM NaCl, fol-
lowed by digestion with SUMOstar protease 1 in the pre-
sence of 2 mM DTT. The final protein product was
collected in the flow-through and buffer-exchanged with
PBS using a PD-10 column.
Reticulocyte lysate in vitro translation assay
The ability of rGel-containing toxins to inhibit [3H]leu-
cine incorporation into a protein in a cell-free protein
synthesizing system was assessed as described
previously [20].
Binding affinity
The binding affinity and specificity of rGel-based fusion
toxins containing the combinations of CPE290-319, E9 and
R9 were evaluated by ELISA on both CLDN3 and
CLDN4-positive 2008 cells and CLDN3-knockdown cells.
Rabbit anti-rGel antibody and horseradish peroxidase-
conjugated goat anti-rabbit IgG was used as a tracer in
this assay as described previously [21].
Furin cleavage assay
Various rGel-based fusions containing different linkers
were treated with recombinant human furin (New
England Biolabs, Ipswich, MA) at pH 7.2. A dose of
2 units of purified furin was applied to 25 μg of fusion
protein in each reaction. After incubation for 16 h at
room temperature, the proteins were analyzed by SDS-
PAGE with Coomassie blue staining.
Internalization and intracellular distribution analyses
Immunofluorescence-based internalization studies were
done on 2008 cells. Cells treated with relative fusion toxins
were subjected to immunofluorescent staining with anti-
rGel antibody followed by Texas red-conjugated secondary
antibody. Microscopy was performed at the University of
California San Diego Cancer Center Digital Imaging
Shared Resource using a Zeiss LSM510 confocal micro-
scope system (Carl Zeiss, Inc. Thornwood, NY). Images
were captured from 0.8- μm sections by a 63× lens and
analyzed by SoftWorx software (Applied Precision, Inc).
In vitro cytotoxicity assay
The 2008 cells were plated into 96-well plates at a den-
sity of 2,000 cells/well and allowed to adhere overnight.
The cells were then exposed to different concentrations
of various toxins. After 96 h, the effects of the drugs on
the growth of tumor cells in culture was determined by
the same Cell Counting Kit-8 (CCK-8) method as
described previously [12].
Results
Construction, expression and purification of rGel-based
fusion proteins
As illustrated in Figure 1A, the initial rGel-based fusion
toxins consisted of a flexible G4S linker tethering the
C-terminus of CPE290-319 to the N-terminus of rGel.
The 30 amino acid CPE290-319 peptide is abbreviated in
this paper as “CPE”. The CPE-G4S-rGel construct was
further engineered by replacing G4S with the furin-
cleavable cell-penetrating sequence R9 to make CPE-R9-
rGel. Vectors expressing other variants containing com-
binations of CPE, E9, G4S and R9 were constructed by
splicing overlap extension PCR (SOE-PCR). Each con-
tained an N-terminal histidine tag to assist purification
followed by a SUMO protease cleavage site that allowed
subsequent removal of the histidine tag. Following
expression in E. coli, purification and SUMO cleavage to
remove the 6×His tag, the final purified products of all
the rGel-based fusion toxins migrated on SDS-PAGE at
the expected molecular weights of 28.2, 31.9, 33.0, 29.6,
31.3, and 34.4 kDa, respectively, for rGel, CPE-G4S-rGel,
CPE-R9-rGel, R9-rGel, E9-G4S-R9-rGel and CPE-E9-G4S-
R9-rGel (Figure 1B).
Binding activity
To ensure that the CPE-containing fusion toxins retained
receptor binding, their ability to bind to a human ovarian
carcinoma cell line was assessed using an ELISA-based
binding assay (Figure 2A). The 2008 ovarian cancer cell
line expresses both CLDN3 and CLDN4, and we have pre-
viously reported on the subline 2008-CLDN3KD-4.5, in
which the expression of CLDN3 was knocked down using
a lentiviral vector expressing a short hairpin RNA targeted
to CLDN3 mRNA [12]. These isogenic CLDN3-positive
and negative cells were exposed to graded concentrations
of the fusion toxins, after washing the binding was assessed
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by determining the amount of cell-bound toxin by reaction
with an anti-rGel antibody. Equilibrium dissociation con-
stants were calculated using GraphPad Prism, v4.03. The
affinity of CPE-G4S-rGel, CPE-R9-rGel, and CPE-E9-G4S-
R9-rGel for CLDN-positive 2008 cells was similar with a Kd
value of 13.63, 14.73 and 10.57 nmol/L, respectively. The
Kd values are consistent with a previous report (Ka =
1.49 × 108 M-1) based on an 125I-CPE saturation binding
assay [22]. In contrast, the binding of CPE-containing tox-
ins to CLDN3-knockdown cells was markedly reduced
(Figure 2B) suggesting that the binding specificity is depen-
dent on the expression of the claudin receptors on the
tumor cell membrane.
Protein synthesis inhibitory activity
The biological activity of toxins can be severely compro-
mised when incorporated into fusion constructs. To
examine the N-glycosidic activity of the rGel component
of the fusion toxins, these materials were added to an in
vitro protein translation assay in which [3H] leucine is
incorporated into isolated rabbit reticulocytes. Inhibition
curves for the fusion constructs CPE-G4S-rGel, CPE-R9-
rGel, R9-rGel, E9-G4S-R9-rGel and CPE-E9-G4S-R9-rGel
were compared to that of native rGel. As shown in
Figure 2C, the IC50 values for the six molecules were
found to be virtually identical (71.2, 71.6, 75.6, 81.0,
82.2, 88.4 pmol/L, respectively, for rGel, CPE-G4S-rGel,
CPE-R9-rGel, R9-rGel, E9-G4S-R9-rGel and CPE-E9-G4S-
R9-rGel) although the shape of the inhibition curve for
CPE-R9-rGel was slightly different from the others indi-
cating that no loss of toxin activity occurred as a result
of fusing rGel to the targeting moieties.
In vitro cleavage of rGel-based toxins by furin
To investigate the susceptibility of various chimeric tox-
ins to proteolytic cleavage, the purified fusion proteins
were subjected to proteolysis with recombinant furin in
a physiological buffer at pH 7.2. As shown in Figure 3,
CPE-R9-rGel, R9-rGel, E9-G4S-R9-rGel and CPE-E9-G4S-
R9-rGel were all cleaved efficiently. In contrast, CPE-
G4S-rGel, in which CPE is fused with rGel through a
G4S linker was not cleaved. Thus, the R9 linker was sen-
sitive to furin cleavage even at pH 7.2 whereas the G4S
was found to be resistant to the action of this protease.
Stability analysis and cellular uptake of rGel-based toxins
Stability of various rGel fusion constructs in tissue cul-
ture medium and their subsequent intracellular accumu-
lation after endocytosis was assessed by Western blot
analysis using an anti-rGel antibody (Figure 4A). The
rGel fusion peptides were added to 2008 cells growing
in RPMI medium containing 5% fetal bovine serum for
a period of 6 h at a concentration of 1 μM, all the
fusion proteins stayed largely intact in the medium with-
out significant degradation suggesting that little or no
proteolytic cleavage occurred outside the cultured cells.
However, only CPE-R9-rGel and R9-rGel were detected
inside the cells after a 6 h exposure indicating that
R9 promotes cellular uptake of the cargo molecule. This
result indicates that, in the absence of the charge neu-
tralization provided by the E9, the R9 moiety markedly
enhances the cellular accumulation of rGel, but that
addition of the E9 sequence is quite effective at blocking
this effect. Of note is the fact that the vast majority of
the intracellular rGel remained undegraded.
Cellular accumulation of the various fusion proteins was
also analyzed by immunofluorescent staining (Figure 4B).
The ovarian 2008 cells were exposed to each test protein
at a concentration of 250 nM for 6 h at 37°C and, follow-
ing fixation, they were stained with an anti-gelonin anti-
body followed by a secondary Texas red-conjugated
antibody prior to examination on a deconvoluting micro-
scope. Figure 4B shows the relative amount and intracellu-
lar distribution of rGel following incubation with rGel,
CPE-G4S-rGel, and R9-rGel. Control cells not exposed to
any of the proteins showed no intracellular staining (data
not shown), as was also the case for cells exposed to rGel.
Figure 1 Preparation of rGel-based series fusion toxins .
A. Schematic diagram of the fusion constructs containing CPE, E9,
R9 and rGel. B. SDS-PAGE analysis of the final purified products of
the above toxins.
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Cells exposed to CPE-G4S-rGel contained a small amount
of dispersed punctuate intracellular staining suggestive of
localization within vesicular structures. In contrast, exten-
sive diffuse intracellular staining indicative of cytosolic
localization was observed in the cells exposed to R9-rGel.
Thus, as detected by the immunofluorescent staining, CPE
was able to enhance the cellular accumulation of rGel
despite the fact that this could not be detected by Western
blot analysis. However, consistent with the Western blot
analysis, CPE was far less effective than the R9 moiety.
In vitro cytotoxicity
The cytotoxicity of the various fusion proteins was
assessed by testing their ability to slow the growth of
the 2008 cells. Cells were cultured for 72 h with increas-
ing concentrations of each purified fusion protein and
Figure 2 Characterization and comparison of rGel-based fusion toxins. A. Evaluation of the binding of the fusion constructs CPE-G4S-rGel
(solid up-side-down triangle), CPE-R9-rGel (solid circle), CPE-E9-G4S-R9-rGel (solid upright triangle) and rGel (open square) to 2008 cells by whole-
cell ELISA. B. Evaluation of the binding of the fusion constructs CPE-G4S-rGel (solid up-side-down triangle), CPE-R9-rGel (solid circle), CPE-E9-G4S-
R9-rGel (solid upright triangle) and rGel (open square) to 2008-CLDN3KD-4.5 cells by whole-cell ELISA. C. The enzymatic (N-glycosidase) activity of
the rGel component of the fusions (solid sqaure, rGel; solid upright triangle, CPE-G4S-rGel; solid circle, CPE-R9-rGel; open square, R9-rGel; open
upright triangle, E9-G4S-R9-rGel; open up-side-down triangle, CPE-E9-G4S-R9-rGel) as assessed using rabbit reticulocyte lysate assay.
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the percent survival in comparison to controls treated
only with phosphate buffered saline was determined in
CCK-8 assays. As shown in Figure 5A, despite the ability
of the CPE peptide to enhance rGel uptake as detected
by the immunofluorescent staining, CPE-G4S-rGel pro-
duced no greater reduction in survival than rGel itself.
This indicates that the additional amount of rGel
brought into the cell through the interaction of CPE
with claudins 3 and 4 was sequestered in an intracellular
compartment from which it could not escape to reach
the ribosome and inhibit protein synthesis.
Strikingly, when the R9 moiety was added to the
fusion protein it enhanced cell killing 10-fold over that
attained with CPE-G4S-rGel alone (IC50 78 nM versus
715 nM). To determine whether the enhanced cytotoxic
activity of CPE-R9-rGel was still dependent on the speci-
fic binding of CPE to the claudin receptors on the cell
surface, R9-rGel was included in the cytotoxicity study.
Intriguingly, R9-rGel without the CPE targeting moiety
displayed even more potent cell killing with an IC50 of
38 nM. This is consistent with the well known ability of
arginine-rich peptides to efficiently translocate cargo
through cell membranes. However, the addition of the
R9 moiety clearly did not assist in the goal of achieving
claudin-dependent cytotoxicity.
Neutralization of R9 to enhance specificity
Given that the R9 moiety was so effective at enhancing
uptake, we reasoned that it would likely also be good at
releasing rGel from the compartment into which CPE
delivered it. However, to make use of the R9 sequence
in this manner it is necessary to mask the R9 until after
CPE-mediated and claudin-dependent endocytotic
uptake. The addition of a 9 poly-glutamic acid sequence
(E9) to the R9 moiety so as to neutralize its positive
charge has previously been shown to disable the ability
of R9 to enter cells [18]. We explored the use of this
approach to block R9 non-specific cell membrane pene-
tration until the toxin had undergone internalization
mediated by the ligand-receptor binding and ended up
in endosomes. The first step was to prove that E9 could
in fact mask the cell-penetrating capacity of the R9 in
2008 cells. To this end an E9-G4S-R9-rGel fusion protein
was produced and tested for cytotoxicity. The addition
of the E9 through a G4S linker to R9-rGel increased the
IC50 by 5.3-fold from 38 nM to 202 nM indicating that
the inhibitory E9 domain can largely neutralize the
R9 domain (Figure 5A). Addition of CPE to the E9-G4S-
R9-rGel fusion protein further reduced the IC50 to
482 nM consistent with the concept that the CPE
directs the CPE-E9-G4S-R9-rGel to intracellular vesicles
from which it has difficulty escaping. To confirm
this, the 2008 cells were incubated with an
IC10 concentration of CPE-E9-G4S-R9-rGel (31.25 nM)
for 6 h and then exposed to a non-toxic concentration
(50 uM) of the endosomolytic reagent chloroquine for
16 h. As shown in Figure 5B, addition of chloroquine
increased the inhibition of growth produced by this con-
centration of CPE-E9-G4S-R9-rGel from 10% to 76%.
Thus, CPE provides targeting to claudin-expressing
tumor cells, R9 provides a mechanism for getting out of
intracellular compartment, and E9 offers an approach to
masking the non-specific toxicity of R9-rGel. However, a
mechanism for cleaving the CPE-E9 fragment from the
R9-rGel fragment once inside the cell is still needed.
Protease-dependent cleavage
One approach to separating CPE-E9 from R9-rGel after
endocytosis is to introduce a sequence between the
E9 and R9 that is cleavable by a protease found in the
compartment into which CPE sequesters the fusion pro-
tein. Despite the fact that the R9 sequence is itself a sub-
strate for the endosomal/lysosomal protease furin,
clearly this reaction was insufficient to release significant
amounts of R9-rGel. To this end, a series of fusion pro-
teins were produced containing sequences previously
reported to be substrates for various endosomal/lysoso-
mal proteases. In an attempt to make the R9 sequence
itself a better protease substrate the R9 was modified to
the optimum furin-cleavable sequence RRKRRRRRR. In
a second attempt, the G4S linker was replaced with a
GFLG sequence that is cleavable by endosomal cathe-
psin B. Finally, both were introduced into a third ver-
sion of the fusion protein as CPE-E9-GFLG-R2KR6-rGel.
However, when tested against 2008 cells, none of these
further modifications significantly enhanced the cyto-
toxicity of the CPE-E9-G4S-R9-rGel. We then tried
Figure 3 SDS-PAGE analysis of in vitro furin cleavage of rGel-
based fusion toxins. Purified proteins were incubated with
recombinant furin at room temperature for 16 h at pH 7.2.
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inserting a 10-residue furin cleavable sequence from the
diphtheria toxin translocation domain (A187GNRV
RRSVG196, Fdt) between the CPE fragment and the rGel.
A recombinant immunoproapoptotic protein containing
this sequence was previously shown to result in more
potent cell killing activity than those with other furin-sen-
sitive sequences [17]. However, introduction of the Fdt
sequence previously reported to enhance endosomal
escape also failed to enhance the cytotoxicity of CPE-rGel.
Discussion
Claudin 3 and 4 are of particular interest as targets for the
delivery of protein toxins because they are both
consistently over-expressed on some types of tumors and,
once bound to their ligand, are rapidly internalized by an
endocytotic process. A fusion toxin in which the protein
synthesis inhibitory factor (PSIF) was attached to a
C-terminal fragment of CPE (C-CPE) was capable of indu-
cing cytolysis in CLDN3/4-expressing MCF-7 human
breast cancer cells [10] implying that C-CPE-PSIF must
have entered the cytosol. However, the work reported here
has exposed some limitations to this approach primarily
related to the challenge of getting toxic proteins out of
endosomal compartments. We opted to explore CPE-
based targeting using the protein toxin gelonin since the
requirement for gelonin to escape endosomal/lysosomal
Figure 4 Stability analysis and intracellular uptake of rGel fusion toxins. A. Extent of degradation following exposure of 1 μM to 2008 cells
for 6 h. The medium and cells were subjected to Western blot analysis with anti-rGel antibody. B. Internalization of rGel, CPE-G4S-rGel and R9-
rGel into 2008 cells. Cells were treated with 250 nM of each fusion toxin for 6 h and stained with rabbit anti-gelonin antibody and Texas red-
coupled anti-rabbit secondary antibody. Nuclei were stained with Hoechst 33342 (blue).
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compartments to reach the ribosome is well-established,
and this toxin has been successfully used to make a variety
of immunotoxins in the past [2,14,23,24].
The various fusion proteins tested turned out to be quite
stable in the presence of cells and tissue culture media, and
those that did get into the 2008 cells were not extensively
degraded intracellularly. We have previously documented
that the 2008 human ovarian cancer cells express claudin
3 and 4 at levels that are readily detectable by Western
blot analysis [12]. Despite the fact that the addition of CPE
did not enhance the cellular accumulation of rGel as mea-
sured by Western blot analysis, enhanced uptake relative
to native rGel was clearly detected by immunofluorescent
staining with an anti-gelonin antibody. The pattern of dis-
persed punctuate staining is consistent with accumulation
in the endosomal/lysosomal compartment. However, this
degree of enhancement failed to increase the cytotoxicity
of the rGel, suggesting that the rGel could not escape from
the compartment into which CPE delivered it. The fact
that the treatment with a low concentration of chloro-
quine, which permeabilizes endosomes, enhanced the toxi-
city of CPE-E9-G4S-R9-rGel provides a second line of
evidence that CPE delivers rGel into a subcellular compart-
ment from which it cannot readily escape. It is noteworthy
that chloroquine, the anti-malaria drug clinically used in
humans, can also be applied to achieve endosome disrup-
tion in vivo without severe side effects [25], thus holding
promise for further optimization and development as a
combined therapy with CPE-based toxins.
Arginine-rich peptides have been extensively used to
enhance cellular uptake of various types of cargo, and there
is a reasonable presumption that they can deliver cargo out
Figure 5 Cytotoxicity of rGel-based fusion toxins. A. In vitro cytotoxicity of various rGel-based series fusion toxins against 2008 cells (solid
upright triangle, rGel; solid up-side-down triangle, CPE-G4S-rGel; solid circle, R9-rGel; solid diamond, CPE-R9-rGel; solid sqaure, E9-G4S-R9-rGel; and
×, CPE-E9-G4S-R9-rGel). B. Enhancement of the cytotoxicity of CPE-E9-G4S-R9-rGel to 2008 cells by the endosomolytic reagent chloroquine. Cells
were treated with 31.25 nM CPE-E9-G4S-R9-rGel for 6 h, washed with complete medium 3 times and subsequently incubated with 50 μM
chloroquine for 16 h. Afterwards, the chloroquine-containing medium was also removed and replaced with fresh growth medium after 3 times
washing. The cytotoxic effects were determined by CCK-8 assay at 72 h after exposure to CPE-E9-G4S-R9-rGel.
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of subcellular compartments as well although there is little
information on this point. When R9 was added to either
rGel alone or the CPE-G4S-rGel fusion protein it markedly
increased uptake and cytotoxicity. However, it also obliter-
ated the selectivity afforded by the CPE component (data
not shown). In an attempt to mask the R9 sequence until
the CPE had successfully delivered the rGel into the cell,
we utilized the strategy of neutralizing the charge on
R9 with an E9 sequence previously demonstrated by Tsien
and colleagues [18,26]. In this approach the tumor selectiv-
ity is achieved by including a sequence between the R9 and
E9 that is cleaved by a matrix metalloproteinase to remove
the negatively charged E9 glutamate sequence allowing
subsequent tumor penetration of a cargo by R9. Our design
differs in that the recruitment of the fusion toxin to tumor
cells is mediated through ligand-receptor interaction,
R9 provides a mechanism for getting out of intracellular
compartment and E9 offers an approach to masking the
non-specific toxicity of R9-rGel. The addition of E9,
attached via a flexible G4S linker, did indeed substantially
reduce the toxicity of R9-rGel and CPE-R9-rGel confirming
in this model the observation that the electrostatic interac-
tion between the E9 and R9 sequences when they are teth-
ered together disables the ability of R9 to translocate cargo
across lipid membranes [18,26]. However, despite the fact
that the R9 sequence itself is a substrate for the endoso-
mal/lysosomal protease furin, it appears that R9-rGel was
not released from CPE-E9-G4S-R9-rGel after cellular
uptake. Given the great potency of R9-rGel, one would
expect even a modest release to be detected as an increase
in cytotoxicity. Interestingly, neither a modification of the
R9 sequence directed at enhancing its cleavage by furin nor
the use of a GFLG linker increased the cytotoxicity of rGel
delivered into the intracellular compartment to which it is
directed by CPE. Thus, if the use of R9 to enhance release
of rGel or other protein toxins from intracellular compart-
ment is to be successful, a sequence that is more readily
cleaved needs to be found or another approach to linking
the E9 to the R9 developed. Importantly, the CPE-E9-linker-
R9-rGel proteins provide an excellent model system with
which to test other types of linkers.
Conclusions
The results of the studies reported here are relevant to
the broad challenge of finding ways of getting therapeutic
molecules out of intracellular compartments. There are
now a myriad of ways of enhancing the endocytosis of
various toxins including attachment to antibodies and
ligands for receptors of many types. However, endoso-
mal/lysosomal entrapment and release remains poorly
defined. Control of this step offers a substantial opportu-
nity for the development of novel cancer therapeutics
that traverse the endosomal/lysosomal compartment of
tumor cells. Antibodies to the extracellular domain of
CLDN3 and CLDN4 have now been developed [27,28] to
which rGel could potentially be linked and it is possible
that endocytosis of an antibody rGel complex would
deliver rGel into a compartment from which it is more
readily released.
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